Who We Are
EveryONE Medicines was founded to industrialize individualized medicines and scale what was once thought impossible.
Our story begins with Mila. After a happy and seemingly healthy first few years of childhood, Mila was diagnosed with a rare fatal neurodegenerative disease. In a ground-breaking race against time, Dr. Timothy Yu of Boston Children’s Hospital developed milasen, an antisense oligonucleotide targeting Mila’s unique mutation. Mila became the first person in the world to receive a medicine tailored to just one person. Since then, Mila’s mother, Julia Vitarello, has been on a mission to turn the work for Mila into a new mainstream way of solving the global crisis of rare disease in children. Julia co-founded EveryONE Medicines with the hope of creating a viable business model to bring this approach to all patients who could benefit. Together, we are working toward a future where individualized medicines are routine.
- Mila's Miracle Foundation
- Mila to More short documentary
- Milasen: The drug that went from idea to injection in 10 months
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives
- The quest for the era of personalised medicine
The company was co-founded by Mila’s mom, who helped drive the development of milasen, and Dr. Tim Yu, the scientist who designed milasen — the first medicine developed for a single patient. Together, they recognized that while the science to create individualized medicines existed, there was no system to deliver them at scale.
To ensure that individualized medicines reach everyone in need - when they need them, where they need them.
A New Category of Company
EveryONE Medicines is not a traditional biotech company.
We focus on process, not product — creating standardized, regulator-aligned development pathways where the same process can be used to develop different medicines for different diseases and mutations.
We take an end-to-end approach, spanning patient identification, modality matching, drug design, clinical delivery, regulatory approval, and reimbursement.
Our platform is modality-agnostic, beginning with antisense oligonucleotides and expanding to other genetic medicine approaches as appropriate.
We are actively helping to shape regulatory and payer frameworks to relieve parents and clinicians of the burden of becoming drug developers and fundraisers so children can access individualized medicines at scale.
